Completed PHASE4 INTERVENTIONAL 1-arm NCT00967538

Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments

Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab

Sponsor: Amgen

Conditions Psoriasis

Interventions etanercept 50 mg

Updated 6 times since 2017 Last updated: Jul 23, 2014 Started: Sep 30, 2009 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00967538, this PHASE4 trial focuses on Psoriasis and remains completed. Sponsored by Amgen, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Innovaderm Research Inc.

Data source: Innovaderm Research Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Calgary, Canada , Greater Sudbury, Canada , Halifax, Canada , Hamilton, Canada , London, Canada , Markham, Canada , Montreal, Canada , North York, Canada , Québec, Canada , Saint-Hyacinthe, Canada and 4 more locations